The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Oct 27

PMID 36293225

Authors

Ioana Rusu

Radu Pirlog

Paul Chiroi

Andreea Nutu

Vlad Radu Puia

Alin Cornel Fetti

Daniel Radu Rusu

Ioana Berindan-Neagoe

Nadim Al Hajjar

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver pathology worldwide. Meanwhile, liver cancer represents the sixth most common malignancy, with hepatocellular carcinoma (HCC) as the primary, most prevalent subtype. Due to the rising incidence of metabolic disorders, NAFLD has become one of the main contributing factors to HCC development. However, although NAFLD might account for about a fourth of HCC cases, there is currently a significant gap in HCC surveillance protocols regarding noncirrhotic NAFLD patients, so the majority of NAFLD-related HCC cases were diagnosed in late stages when survival chances are minimal. However, in the past decade, the focus in cancer genomics has shifted towards the noncoding part of the genome, especially on the microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), which have proved to be involved in the regulation of several malignant processes. This review aims to summarize the current knowledge regarding some of the main dysregulated, noncoding RNAs (ncRNAs) and their implications for NAFLD and HCC development. A central focus of the review is on miRNA and lncRNAs that can influence the progression of NAFLD towards HCC and how they can be used as potential screening tools and future therapeutic targets.

Citing Articles

Evaluating the roles of microRNAs associated with nonalcoholic fatty liver disease in hepatocellular carcinoma tumorigenesis: a systematic review and network analysis.

Peng Q, Zhu X, Jiang Y, Peng M, Zheng D, Wang X Front Med (Lausanne). 2024; 11:1462513.

PMID: 39618816 PMC: 11604432. DOI: 10.3389/fmed.2024.1462513.

Long Non-Coding RNAs in Non-Alcoholic Fatty Liver Disease; Friends or Foes?.

Soltanieh S, Khastar S, Kaur I, Kumar A, Bansal J, Fateh A Cell Biochem Biophys. 2024; 83(1):279-294.

PMID: 39377981 DOI: 10.1007/s12013-024-01555-8.

mA-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma.

Lin Z, Huang Z, Qiu J, Shi Y, Zuo D, Qiu Z J Exp Clin Cancer Res. 2024; 43(1):206.

PMID: 39054531 PMC: 11271202. DOI: 10.1186/s13046-024-03134-4.

Unveiling the cancer risk nexus of the steatotic liver.

Kim J, Seki E Trends Endocrinol Metab. 2024; 35(8):708-719.

PMID: 38531699 PMC: 11321945. DOI: 10.1016/j.tem.2024.02.017.

Molecular mechanisms in MASLD/MASH-related HCC.

Wang X, Zhang L, Dong B Hepatology. 2024; .

PMID: 38349726 PMC: 11323288. DOI: 10.1097/HEP.0000000000000786.

References

Sun C, Xiao T, Xiao Y, Li Y . Silencing of long non‑coding RNA NEAT1 inhibits hepatocellular carcinoma progression by downregulating SMO by sponging microRNA‑503. Mol Med Rep. 2021; 23(3). PMC: 7821340. DOI: 10.3892/mmr.2020.11807. View

Yoon J, Kim G, Lee Y, Park S, Tak W, Kweon Y . Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma. Biomark Med. 2018; 12(10):1105-1114. DOI: 10.2217/bmm-2018-0096. View

Li L, Jia L, Ding Y . Upregulation of miR-375 inhibits human liver cancer cell growth by modulating cell proliferation and apoptosis via targeting ErbB2. Oncol Lett. 2018; 16(3):3319-3326. PMC: 6096281. DOI: 10.3892/ol.2018.9011. View

Sun T, Xie H, Li Z, Kong L, Gou X, Li D . miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma. Am J Transl Res. 2017; 9(1):103-114. PMC: 5250707. View

Yin J, Chen X, Zhang F, Zhao M . RMRP inhibition prevents NAFLD progression in rats via regulating miR-206/PTPN1 axis. Mamm Genome. 2022; 33(3):480-489. DOI: 10.1007/s00335-022-09945-0. View

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

Tsai W, Hsu P, Lai T, Chau G, Lin C, Chen C . MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009; 49(5):1571-82. DOI: 10.1002/hep.22806. View

de Martel C, Maucort-Boulch D, Plummer M, Franceschi S . World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015; 62(4):1190-200. PMC: 5019261. DOI: 10.1002/hep.27969. View

10.

Burra P, Becchetti C, Germani G . NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep. 2020; 2(6):100192. PMC: 7607500. DOI: 10.1016/j.jhepr.2020.100192. View

11.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

12.

Erhartova D, Cahova M, Dankova H, Heczkova M, Mikova I, Sticova E . Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation. PLoS One. 2019; 14(11):e0224820. PMC: 6839850. DOI: 10.1371/journal.pone.0224820. View

13.

Bechmann L, Hannivoort R, Gerken G, Hotamisligil G, Trauner M, Canbay A . The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2011; 56(4):952-64. DOI: 10.1016/j.jhep.2011.08.025. View

14.

Tsai W, Hsu S, Hsu C, Lai T, Chen S, Shen R . MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122(8):2884-97. PMC: 3408747. DOI: 10.1172/JCI63455. View

15.

Liu Y, Reeves H, Burt A, Tiniakos D, McPherson S, Leathart J . TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014; 5:4309. PMC: 4279183. DOI: 10.1038/ncomms5309. View

16.

Pirlog R, Drula R, Nutu A, Calin G, Berindan-Neagoe I . The Roles of the Colon Cancer Associated Transcript 2 (CCAT2) Long Non-Coding RNA in Cancer: A Comprehensive Characterization of the Tumorigenic and Molecular Functions. Int J Mol Sci. 2021; 22(22). PMC: 8620102. DOI: 10.3390/ijms222212491. View

17.

Huang Z, Zhou J, Peng Y, He W, Huang C . The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020; 19(1):77. PMC: 7161154. DOI: 10.1186/s12943-020-01188-4. View

18.

Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H . Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel). 2020; 10(8). PMC: 7459689. DOI: 10.3390/diagnostics10080579. View

19.

Guo S, Chen W, Luo Y, Ren F, Zhong T, Rong M . Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients. Int J Clin Exp Pathol. 2015; 8(5):5395-402. PMC: 4503113. View

20.

Susman S, Pirlog R, Leucuta D, Mitre A, Padurean V, Melincovici C . The role of p-Stat3 Y705 immunohistochemistry in glioblastoma prognosis. Diagn Pathol. 2019; 14(1):124. PMC: 6829927. DOI: 10.1186/s13000-019-0903-4. View